Patents Assigned to Bristol-Myers
  • Methods for the preparation of HIV attachment inhibitor piperazine prodrug compound
    Patent number: 9376458
    Abstract: A method for making the compound is set forth utilizing the starting material
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 28, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Martin D. Eastgate, Michael S. Bultman, Ke Chen, Dayne Dustan Fanfair, Richard J. Fox, Thomas E. La Cruz, Boguslaw M. Mudryk, Christina Ann Risatti, James H. Simpson, Maxime C. Soumeillant, Jonathan Clive Tripp, Yi Xiao
  • Imidazopyridazinecarbonitriles useful as kinase inhibitors
    Patent number: 9371328
    Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazopyridazines inhibit protein kinase activity thereby making them useful as anticancer agents.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: June 21, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Libing Chen, Ashvinikumar V. Gavai, Liqi He, Soong-Hoon Kim, Andrew James Nation, Yufen Zhao, Litai H. Zhang
  • Dihydropyridinone MGAT2 inhibitors
    Patent number: 9365558
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: June 14, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Lidet A. Negash
  • Pyrimidine Compounds for the Treatment of Hepatitis C
    Publication number: 20160159769
    Abstract: The disclosure provides compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: March 5, 2014
    Publication date: June 9, 2016
    Applicant: Bristol-Myers Squibb Company
    Inventors: TAO WANG, CHRISTOPHER ALLARD
  • Bicyclic compounds
    Patent number: 9359286
    Abstract: Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is —OH or —OP(O)(OH)2. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: June 7, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventor: Hai-Yun Xiao
  • Substituted adipic acid amides and uses thereof
    Patent number: 9346852
    Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A is a five to eight membered monocyclic or a nine to twelve membered bicyclic heterocyclic ring, as further defined herein; Y is S, CH2, or CH; Z is CH or N; R7 and R9 are hydrogen or (C1-C6)alkyl; R2 is (C1-C6)alkoxy, OH, CN, (C1-C6)alkyl, halogen, or CF3; r and s are 0, 1, or 2; and R1 and R3 are as further defined herein. These compounds are agonists, partial agonists and/or modulators of the NPY4 receptor and may be used for the treatment and prophylaxis of obesity, food intake, and other diseases and conditions modulated by the NPY4 receptor.
    Type: Grant
    Filed: March 13, 2012
    Date of Patent: May 24, 2016
    Assignee: Bristol-Myers Scuibb Company
    Inventors: Chongqing Sun, William R. Ewing, Scott A. Bolton, Zhengxiang Gu, Yanting Huang, Natesan Murugesan, Yeheng Zhu
  • Methods for the selection of binding proteins
    Patent number: 9347058
    Abstract: This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: May 24, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventor: Dasa Lipovsek
  • Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
    Patent number: 9346795
    Abstract: Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 24, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhen-Wei Cai, Andrew J. Tebben, Heidi L. Perez, Liping Zhang, Gretchen M. Schroeder, Donna D. Wei
  • IAP antagonists
    Patent number: 9345740
    Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: May 24, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventor: Kyoung S. Kim
  • Hepatitis C virus inhibitors
    Patent number: 9340520
    Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: May 17, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Omar D. Lopez, John A. Bender, Makonen Belema
  • CRYSTALLINE FORMS OF N,N-DICYCLOPROPYL-4-(1,5-DIMETHYL-1H-PYRAZOL-3-YLAMINO)-6-ETHYL-1-METHYL-1,6-DIHYDROIMIDAZO[4,5-D]PYRROLO[2,3-B]PYRIDINE-7-CARBOXIMIDE FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS
    Publication number: 20160130272
    Abstract: Crystalline form, Form N-2, of N,Ndicyclopropyl-4-(1,5-dimethyl-1Hpyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising Form N-2 of Compound I as well as a method of using the Form N-2 of Compound I in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis.
    Type: Application
    Filed: May 28, 2014
    Publication date: May 12, 2016
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventor: Shella Tameze
  • Hepatitis C virus inhibitors
    Patent number: 9334279
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: May 10, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Eric P. Gillis, Michael S. Bowsher, Paul Michael Scola
  • Substituted tetrahydrocarbazole and carbazole carboxamide compounds
    Patent number: 9334290
    Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: May 10, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G Batt, Myra Beaudoin Bertrand, George Delucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
  • Inhibitors of type 2 vascular endothelial growth factor receptors
    Patent number: 9328157
    Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: May 3, 2016
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
  • Hepatitis C virus inhibitors
    Patent number: 9326973
    Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: May 3, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Piyasena Hewawasam, John F. Kadow, Omar D. Lopez, Nicholas A. Meanwell, Yong Tu, Alan Xiangdong Wang, Ningning Xu, Samayamunthula Venkata Satya Arun Kumar Gupta, Pothukanuri Srinivasu, Indasi Gopi Kumar, Ponugupati Suresh Kumar, Makonen Belema, Robert A. Fridell, Min Gao, Julie A. Lemm, Donald R. O'Boyle, II, Jin-Hua Sun, Chunfu Wang, Ying-Kai Wang
  • Apixaban formulations
    Patent number: 9326945
    Abstract: Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 ?m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: May 3, 2016
    Assignees: Bristol-Myers Squibb Company, Pfizer Inc.
    Inventors: Jatin Patel, Charles Frost, Jingpin Jia, Chandra Vemavarapu
  • Combination of anti-CTLA4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
    Patent number: 9320811
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: April 26, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventor: Maria Jure-Kunkel
  • Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
    Patent number: 9315519
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: April 19, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald J. P. Pinto, Charles G. Clark, Michael J. Orwat, Leon M. Smith, II, William R. Ewing
  • Alkyl-amide-substituted pyridyl compounds useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 9315494
    Abstract: Compounds having the following formula (I): or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: April 19, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ryan M. Moslin, Shuqun Lin, David S. Weinstein, Stephen T. Wrobleski, Yanlei Zhang, John S. Tokarski, Michael E. Mertzman
  • Stable subcutaneous protein formulations and uses thereof
    Patent number: 9309316
    Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manisha D. Dali, Charles E. Dahlheim, Sunita Borsadia, Vijay H. Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar